Please login to the form below

Launch Excellence 2020

In this special pack, we provide a comprehensive outlook of launch excellence. We cover topics ranging from gathering effective insights, to understanding the current landscape, and the importance of pre-launch strategy for improving relationships between the customer and the brand.

In the past year, the competition in biosimilars and complex generics has complicated the launch landscape. An abundance of discoveries coupled with radically evolving stakeholder needs is also straining the traditional pharmaceutical launch.

In this special pack, we provide a comprehensive outlook of launch excellence. We cover topics ranging from gathering effective insights, to understanding the current landscape, and the importance of pre-launch strategy for improving relationships between the customer and the brand.

The report also features interviews with key players such as organisational transformation expert Philip Atkinson. He shares his unique perspective on the importance of structuring agile organisational change to help pharmaceutical companies adapt and stay competitive.

These articles are complemented by case studies curated by our experienced in-house team.

In this publication, we help you answer the following questions:

  • Are you prepared for a successful launch?
  • How can you use insights to understand customers decision-making behaviour?
  • What are you missing in your CAR-T service launch?
  • How do you stay competitive with a lean pharmaceutical launch?
  • Multi-indication launches – how do you navigate in this space?

DOWNLOAD LAUNCH EXCELLENCE 2020 HERE

20th November 2019

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
Unpacking rare diseases in the first edition of Delta magazine
Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health
Great creative is effective creative. And effective creative is affective creative
Our creative approach at Fishawack Health is Affective Creativity. Creative crafted to make deep, motivating connections with our target audience. We tap into psychology and combine that with creative craft and expertise and to deliver powerful, engaging work on a conscious as well as a subconscious level.
Blue Latitude Health
How to make an impact at a virtual congress
As hard as congress organisers try, replicating the congress experience on a virtual platform is difficult. Rather than trying to replicate the in-person congress experience, the industry has a real opportunity to innovate, leverage the benefits of digital channels, and approach congresses in a completely different way.
Blue Latitude Health